Abstract
There is a critical need for the development of novel diagnostic and therapeutic strategies for pancreatic ductal adenocarcinoma (PDAC), a devastating disease known for its poor prognosis due to its late presentation and high aggressiveness. MicroRNAs (miRNAs) are a class of short non-coding RNAs that have been implicated in the gene regulation in normal cellular processes as well as cancer pathogenesis. Patterns of miRNA upregulation and downregulation have been found to be unique to specific cancers, including PDAC. MiRNA expression profiling may serve as a new strategy for the diagnosis and prognosis of PDAC cases. In addition, the role of miRNAs in important cellular processes such as cell development, survival, and proliferation may also be utilized for novel therapeutic approaches. This article presents current progress on the role of miRNAs as a biomarker and therapeutic target for PDAC.
Keywords: MicroRNA, pancreatic adenocarcinoma, prognosis, pathogenesis, oncogenic, ultrasound, formalin, metastasis, intratumoral, 2’-Omethoxethyl
Current Signal Transduction Therapy
Title:MicroRNAs and Pancreatic Cancer: Current Research and Future Outlooks
Volume: 7 Issue: 3
Author(s): Wei Li, Kei Satoh, Drake G. LeBrun and Min Li
Affiliation:
Keywords: MicroRNA, pancreatic adenocarcinoma, prognosis, pathogenesis, oncogenic, ultrasound, formalin, metastasis, intratumoral, 2’-Omethoxethyl
Abstract: There is a critical need for the development of novel diagnostic and therapeutic strategies for pancreatic ductal adenocarcinoma (PDAC), a devastating disease known for its poor prognosis due to its late presentation and high aggressiveness. MicroRNAs (miRNAs) are a class of short non-coding RNAs that have been implicated in the gene regulation in normal cellular processes as well as cancer pathogenesis. Patterns of miRNA upregulation and downregulation have been found to be unique to specific cancers, including PDAC. MiRNA expression profiling may serve as a new strategy for the diagnosis and prognosis of PDAC cases. In addition, the role of miRNAs in important cellular processes such as cell development, survival, and proliferation may also be utilized for novel therapeutic approaches. This article presents current progress on the role of miRNAs as a biomarker and therapeutic target for PDAC.
Export Options
About this article
Cite this article as:
Li Wei, Satoh Kei, G. LeBrun Drake and Li Min, MicroRNAs and Pancreatic Cancer: Current Research and Future Outlooks, Current Signal Transduction Therapy 2012; 7 (3) . https://dx.doi.org/10.2174/157436212802481529
DOI https://dx.doi.org/10.2174/157436212802481529 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Branched Peptides for the Modulation of Protein-Protein Interactions: More Arms are Better than One?
Current Medicinal Chemistry MicroRNAs in Lung Cancer and Lung Cancer Bone Metastases: Biomarkers for Early Diagnosis and Targets for Treatment
Recent Patents on Anti-Cancer Drug Discovery Heme Oxygenase-1 in Tumor Biology and Therapy
Current Drug Targets Seeing Genes at Work in the Living Brain with Non-Invasive Molecular Imaging
Current Gene Therapy Recent Advances in Application of Poly-Epsilon-Caprolactone and its Derivative Copolymers for Controlled Release of Anti-Tumor Drugs
Current Cancer Drug Targets Gene Therapy Strategies in Prostate Cancer
Current Gene Therapy Biomarkers Downstream of RAS: A Search for Robust Transcriptional Targets
Current Cancer Drug Targets Interleukin-6/interleukin-6 Receptor Pathway as a New Therapy Target in Epithelial Ovarian Cancer
Current Pharmaceutical Design The Potential for Substance P Antagonists as Anti-Cancer Agents in Brain Tumours
Recent Patents on CNS Drug Discovery (Discontinued) Steroid Regulation of Drug-Metabolizing Cytochromes P450
Current Drug Metabolism Cycloxygenase-2 (COX-2) - A Potential Target for Screening of Small Molecules as Radiation Countermeasure Agents: An In Silico Study
Current Computer-Aided Drug Design GEFT, A Rho Family Guanine Nucleotide Exchange Factor, Regulates Lens Differentiation through a Rac1-Mediated Mechanism
Current Molecular Medicine The Neurotrophic and Antiangiogenic Functions of PEDF: A Reflection of its Variable Phosphorylation States
Current Genomics Simultaneous Interruption of Signal Transduction and Cell Cycle Regulatory Pathways: Implications for New Approaches to the Treatment of Childhood Leukemias
Current Drug Targets Novel Virally Targeted Therapies of EBV-Associated Tumors
Current Cancer Drug Targets Neurotrophic Factor Treatment After Spinal Root Avulsion Injury
Central Nervous System Agents in Medicinal Chemistry The Induction and Repair of DNA Interstrand Crosslinks and Implications in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Recent Patents Involving Virus Nucleotide Sequences; Host Defense, RNA Silencing and Expression Vector Strategies
Recent Patents on DNA & Gene Sequences Exploiting Substrate Recognition for Selective Inhibition of Protein Kinases
Current Pharmaceutical Design The Potential of Tetrandrine Against Gliomas
Anti-Cancer Agents in Medicinal Chemistry